These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
526 related articles for article (PubMed ID: 28407743)
1. New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. Kroschinsky F; Stölzel F; von Bonin S; Beutel G; Kochanek M; Kiehl M; Schellongowski P; Crit Care; 2017 Apr; 21(1):89. PubMed ID: 28407743 [TBL] [Abstract][Full Text] [Related]
2. [Cancer patients in operative intensive care medicine]. Annecke T; Hohn A; Böll B; Kochanek M Anaesthesist; 2018 Feb; 67(2):83-92. PubMed ID: 29368008 [TBL] [Abstract][Full Text] [Related]
3. [Cancer patients in operative intensive care medicine]. Annecke T; Hohn A; Böll B; Kochanek M Wien Klin Mag; 2018; 21(2):68-77. PubMed ID: 32288864 [TBL] [Abstract][Full Text] [Related]
4. Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer. Gutierrez C; McEvoy C; Munshi L; Stephens RS; Detsky ME; Nates JL; Pastores SM Crit Care Med; 2020 Jan; 48(1):10-21. PubMed ID: 31725440 [TBL] [Abstract][Full Text] [Related]
5. New insight in endocrine-related adverse events associated to immune checkpoint blockade. Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543 [TBL] [Abstract][Full Text] [Related]
6. Immune-related adverse events of antibody-based biological medicines in cancer therapy. Rajagopal D; MacLeod E; Corogeanu D; Vessillier S J Cell Mol Med; 2024 Jul; 28(13):e18470. PubMed ID: 38963257 [TBL] [Abstract][Full Text] [Related]
7. Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy. Iovino L; Thur LA; Gnjatic S; Chapuis A; Milano F; Hill JA J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986127 [TBL] [Abstract][Full Text] [Related]
8. Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians. Hryniewicki AT; Wang C; Shatsky RA; Coyne CJ J Emerg Med; 2018 Oct; 55(4):489-502. PubMed ID: 30120013 [TBL] [Abstract][Full Text] [Related]
10. Supportive care for patients undergoing immunotherapy. Rapoport BL; van Eeden R; Sibaud V; Epstein JB; Klastersky J; Aapro M; Moodley D Support Care Cancer; 2017 Oct; 25(10):3017-3030. PubMed ID: 28707167 [TBL] [Abstract][Full Text] [Related]
11. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage? Michot JM; Lazarovici J; Tieu A; Champiat S; Voisin AL; Ebbo M; Godeau B; Michel M; Ribrag V; Lambotte O Eur J Cancer; 2019 Nov; 122():72-90. PubMed ID: 31634647 [TBL] [Abstract][Full Text] [Related]
12. Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge. Kostine M; Chiche L; Lazaro E; Halfon P; Charpin C; Arniaud D; Retornaz F; Blanco P; Jourde-Chiche N; Richez C; Stavris C Rev Med Interne; 2017 Aug; 38(8):513-525. PubMed ID: 28214182 [TBL] [Abstract][Full Text] [Related]
13. Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies. Fishman JA; Hogan JI; Maus MV Clin Infect Dis; 2019 Aug; 69(6):909-920. PubMed ID: 30520987 [TBL] [Abstract][Full Text] [Related]
14. Potentially fatal complications of new systemic anticancer therapies: pearls and pitfalls in their initial management. Kovac MB; Seruga B Radiol Oncol; 2024 Jun; 58(2):170-178. PubMed ID: 38613842 [TBL] [Abstract][Full Text] [Related]
15. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis. Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061 [TBL] [Abstract][Full Text] [Related]
16. The side effect registry immuno-oncology (SERIO) - A tool for systematic analysis of immunotherapy-induced side effects. Ertl C; Ruf T; Mentzer D; Kong M; Kramer R; Bergwelt-Baildon MV; Subklewe M; Tomsitz D; Ascierto PA; Dummer R; Gogas H; Lebbé C; Long GV; McArthur G; Neilan TG; Ribas A; Robert C; Schadendorf D; Zimmer L; Eigentler T; Grabbe S; Forschner A; Kähler KC; Milani V; Pföhler C; Hassel J; Gutzmer R; Loquai C; Routy B; Furness AJS; Blank C; Wolchok JD; French LE; Hauschild A; Heinzerling L Eur J Cancer; 2024 Mar; 199():113505. PubMed ID: 38262306 [TBL] [Abstract][Full Text] [Related]
17. Acute management of autoimmune toxicity in cancer patients on immunotherapy: Common toxicities and the approach for the emergency physician. Lomax AJ; McNeil C Emerg Med Australas; 2017 Apr; 29(2):245-251. PubMed ID: 28093870 [TBL] [Abstract][Full Text] [Related]
18. Toxicities of chimeric antigen receptor T cells: recognition and management. Brudno JN; Kochenderfer JN Blood; 2016 Jun; 127(26):3321-30. PubMed ID: 27207799 [TBL] [Abstract][Full Text] [Related]